AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

2024-04-25 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

161.7 USD

Average target price

184.3 USD

Spread / Average Target

+13.97%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+5.20%	286B
ELI LILLY AND COMPANY	+28.01%	676B
NOVO NORDISK A/S	+24.27%	559B
JOHNSON & JOHNSON	-7.73%	356B
MERCK & CO., INC.	+15.04%	320B
ASTRAZENECA PLC	+2.62%	213B
NOVARTIS AG	+0.15%	207B
ROCHE HOLDING AG	-9.41%	199B
AMGEN INC.	-8.02%	142B
SANOFI	-3.31%	116B

Other Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:44:20 2024-04-16 pm EDT			5-day change	1st Jan Change
163.2 ^USD	+0.96%		-4.18%	+5.20%

Apr. 12	AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug	MT
Apr. 12	AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine	CI

AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug	Apr. 12	MT
AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine	Apr. 12	CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	Apr. 08	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 05	RE
Boehringer to lay off salespeople as Humira biosimilar sales lag	Apr. 04	RE
AbbVie Flags Hit to Q1 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook	Apr. 04	MT
US takes next step in Medicare drug price negotiations with pharma companies	Apr. 02	RE
Roivant's anti-inflammatory drug succeeds in mid-stage study	Apr. 02	RE
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating	Mar. 27	MT
Deals of the day-Mergers and acquisitions	Mar. 25	RE
Sector Update: Health Care Stocks Decline Late Afternoon	Mar. 25	MT
Top Midday Gainers	Mar. 25	MT
Sector Update: Health Care Stocks Softer in Afternoon Trading	Mar. 25	MT
Top Midday News: Boeing CEO to Step Down; United Airlines to Face Tight FAA Scrutiny; Barclays Upgrades Disney to Overweight; EU Opens Probe Into Apple, Meta, and Google; China to Block Use of Intel, AMD Chips; Ericsson Announces 1,200 Job Cuts in Sweden	Mar. 25	MT
Global markets live: United Airlines, Qualcomm, Amazon, Nissan, Boeing...	Mar. 25
AbbVie to Acquire Landos Biopharma For About $137.5 Million; Landos Shares Jump	Mar. 25	MT
Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie	Mar. 25	DJ
AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million	Mar. 25	DJ
AbbVie to Acquire Landos Biopharma for About $137.5 Million	Mar. 25	MT
AbbVie to Acquire Landos Biopharma for About $137.5 Million	Mar. 25	MT
AbbVie to buy Landos to expand pipeline of immunity-related illnesses	Mar. 25	RE
AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on March 24, 2024.	Mar. 24	CI
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing	Mar. 22	MT
AbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen Deal	Mar. 22	DJ
AbbVie Gets US FDA's Full Approval for Ovarian Cancer Treatment	Mar. 22	MT